Diffuse large B-cell lymphoma (DLBCL) remains a therapeutic challenge, as a substantial proportion of patients experience relapsed or refractory (R/R) disease. Antibody-drug conjugates (ADCs) have emerged as a transformative class of targeted therapy, designed... ...

请注册登录后继续浏览